Treating antidepressant nonresponders with augmentation strategies: An overview

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL. 5, 1998, Pages 5-15

  Thase, Michael E ^a   Howland, Robert H ^a   Friedman, Edward S ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BUSPIRONE; CLOMIPRAMINE; DESIPRAMINE; DEXAMETHASONE; FLUOXETINE; FLUVOXAMINE MALEATE; IMIPRAMINE; KETOCONAZOLE; LITHIUM SALT; MIRTAZAPINE; NEFAZODONE; PAROXETINE; PHENELZINE; PINDOLOL; SERTRALINE; VENLAFAXINE;

ARTICLE; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; HIGH RISK POPULATION; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RATING SCALE; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; BUSPIRONE; DEPRESSIVE DISORDER; DRUG RESISTANCE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; LITHIUM; PINDOLOL; SEVERITY OF ILLNESS INDEX; THYROID HORMONES; TREATMENT OUTCOME;

EID: 0031810791     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Nierenberg AA. Methodological problems in treatment resistant depression research. Psychopharmacol Bull 1990;26:461-464
2. Thase ME, Rush AJ. Treatment resistant depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York. NY: Raven Press. 1995:1081-1097
3. Prien RG, Carpenter LL, Kupter DJ. The definition and operational criteria for treatment outcome of major depressive disorder: a review of the current research literature. Arch Gen Psychiatry 1991;48:796-800
4. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571
5. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
6. Rush AJ, Giles DE, Florio LP, et al. The Inventory for Depressive Symptomatology (IDS): preliminary findings. Psychiatry Res 1986;18:65-87
7. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
9. Endicott J, Spitzer RL, Fleiss JL, et al. The global assessment scale: a procedure for measuring the overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976;33:766-771
10. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale to consensus definitions of terms in major depressive disorder: response, remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991;48: 851-855
11. Rush AJ, Trivedi MI. Treating depression to remission. Psychiatric Annals 1995;25:704-709
12. Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry 1991;52 (5, suppl):28-34
13. Prien RG, Kupfer DJ. Continuation drug therapy for major depressive episodes: how long should it be maintained? Am J Psychiatry 1986;143:18-23
14. Kupfer DJ, Frank E, Perel JM, et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992;49:769-773
15. American Psychiatric Association Practice Guideline for Major Depressive Disorder in Adults. Am J Psychiatry 1993;150(4, suppl):1-26
16. Fava GA. Do antidepressants and antianxiety drugs increase chronicity in affective disorders? Psychother Psychosom 1994;61:125-131
17. Joyce PR, Paykel ES. Predictors of drug response in depression. Arch Gen Psychiatry 1989;46:89-99
18. Thase ME, Kupfer DJ. Characteristics of treatment resistant depression. In: Zohar J, Belmaker RH, eds. Treating Resistant Depression. New York, NY: PMA Publishing: 1987:23-45
19. Thase ME, Howland R. Refractory depression: relevance of psychosocial factors and therapies. Psychiatric Annals 1994;24:232-240
20. Thase ME. The role of Axis II comorbidity in the management of patients with treatment resistant depression. Psychiatr Clin North Am 1996;9: 287-309
21. Basco MR, Rush AJ. Compliance of pharmacotherapy in mood disorders. Psychiatric Annals 1995;25:269-270, 276-279
22. Thase ME, Kupfer DJ. Current status of EEG sleep in the assessment and treatment of depression. In: Burrows GD, Werry JS, eds. Advances in Human Psychopharmacology, vol 4. Greenwich, Ct: JAI Press; 1987:93-148
23. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997;58(suppl 13): 23-29
24. Katz MM, Koslow SH, Frazer A. Onset of antidepressant activity: reexamining the structure of depression and multiple actions of drugs. Depression and Anxiety 1997;4:257-267
25. Quitkin FM, McGrath PJ, Stewart JW, et al. Chronological milestones to guide drug changes: when should clinicians switch antidepressants? Arch Gen Psychiatry 1996;53:785-792
26. Schweizer E, Rickels K, Amsterdam JD, et al. What constitutes an adequate antidepressant trial for fluvoxamine? J Clin Psychiatry 1990;51:8-11
27. Altamura A, Montgomery S, Wernicke J. The evidence for 20 mg a day of fluoxetine as the optimal in the treatment of depression. Br J Psychiatry 1988;153:109-112
28. Fabre LF, Abuzzahab FS, Amin M, et al. Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiatry 1995;38:592-602
29. Dunner DL, Dunbar GC. Optimal dose regimen for paroxetine. J Clin Psychiatry 1992;53(2, suppl):21-26
30. Entsuah AR, Rudolph R, Chitra R. Effectiveness of venlafaxine treatment in a broad spectrum of depressed patients: a meta-analysis. Psychopharmacol Bull 1995;31:759-766
31. Fava M, Rosenbaum JF, Grossbard SJ, et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double blind, controlled study. Am J Psychiatry 1994;151:1372-1374
32. Nierenberg AA, Fava M, Alpert J, et al. Early non-response to fluoxetine predicts poor eight week outcome. Am J Psychiatry 1995;152:1500-1503
33. Brown WA, Harrison W. Are patients who are intolerant to one SSRI intolerant to another? Psychopharmacol Bull 1992;28:253-256
34. Joffe RT, Levitt AJ, Sokolov STH, et al. Response to an open trial of a second SSRI in major depression. J Clin Psychiatry 1996;57:114-115
35. Thase ME, Blomgren SL, Birkett MA, et al. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry 1997;58:16-21
36. Thase ME, Keller MB, Hirschfeld RMA. Double-blind crossover antidepressant study: sertraline vs imipramine. Biol Psychiatry 1997;42:2305
37. Souza FGM, Mander AJ, Goodwin GM. The efficacy of lithium in prophylaxis of unipolar depression: evidence from its discontinuation. Br J Psychiatry 1990;157:718-722
38. Thase ME, Kupfer DJ, Frank E, et al. Treatment of imipramine-resistant recurrent depression, II: an open clinical trial of lithium augmentation. J Clin Psychiatry 1989;50:413-417
39. Goodwin FK, Prange AJ, Post RM, et al. Potentiation of antidepressant effects by L-triiodothyronine in tricyclic nonresponders. Am J Psychiatry 1982;139:34-38
40. Joffe RT, Singer W, Levitt AJ, et al. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993;50:387-393
41. 3 to potentiate tricyclic antidepressant response. J Affect Disord 1987;13:267-272
42. Thase ME, Kupfer DJ, Jarrett DB. Treatment of imipramine-resistant recurrent depression, I: an open clinical trial of adjunctive L-triiodothyronine. J Clin Psychiatry 1989;50:385-388
43. Nierenberg AA. Treatment choice after one antidepressant fails: a survey of northeastern psychiatrists. J Clin Psychiatry 1991;52:383-385
44. Joffe RT, Sokolov STH. Thyroid hormones, the brain, and affective disorders. Crit Rev Neurobiol 1994;8:45-63
45. Satel SL, Nelson JC. Stimulants in the treatment of depression: a critical overview. J Clin Psychiatry 1989;50:241-249
46. Fawcett J, Kravitz HM, Zajecka JM, et al. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J Clin Psychopharmacol 1991;11:127-132
47. Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry 1993;54: 269-271
48. Jacobsen FM. Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry 1991;52:217-220
49. Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 1994;51:248-251
50. Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 1995; 15:217-222
51. Blier P, Bergeron R. The use of pindolol to potentiate antidepressant medication. J Clin Psychiatry 1998;59(suppl 5):16-23
52. Nierenberg AA, Price LH, Charney DS, et al. After lithium augmentation: a retrospective follow-up of patients with antidepressant-refractory depression. J Affect Disord 1990;18:167-175
53. Prudic J, Haskett RF, Mulsant B, et al. Resistance to antidepressant medications and short-term clinical response to ECT. Am J Psychiatry 1996;153:985-992
54. Nierenberg AA, Feighner JP, Rudolph R, et al. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 1994;14:419-423